CURE.X
CURE.X

Biocure Technology Inc.

Statut
Actif
Émis et en Circulation94,000,537
Réservé pour Émission14,510,547
Devise
CSE Indice

À propos

Biocure Technology Inc.

Date d'inscription
10 mai 2010
Social

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.